SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent open-market purchases by Celsius executives and directors have fueled bullish discussion around the shares, while skeptics question whether the buys signal durable confidence given concerns about the core brands sales and management execution. Traders also revive speculation about a Pepsi buyout, but no deal is confirmed.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix shares are under pressure as EyePoints failed wet-AMD trial has heightened doubts about TKI-based treatments, prompting traders to question whether those concerns could extend to Oculars AXPAXLI program. Some investors view the selloff as spillover from a competitors results, while others cite clinical uncertainty and the departure of Oculars chief strategy officer as additional concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided Q3 report and an upbeat 2027 EBITDA outlook are driving CLFs rally. Bulls see improving steel prices and earnings potential, while skeptics warn that debt and the reliance on favorable price forecasts could limit the recovery; traders are also debating whether the move will hold or fade as a sell-the-news rally.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?

Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about...

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

Investors need to pay close attention to SUPN stock based on the movements in the options market lately.

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?

Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?

Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

SUPN vs. TEVA: Which Stock Is the Better Value Option?

New Strong Buy Stocks for August 7th

EDRY, OPBK, SUPN, MSBI and NXRT have been added to the Zacks Rank #1 (Strong Buy) List on August 7th, 2026.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Supernus Pharmaceuticals Inc

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The analyst noted that sponsors must continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health.</li><li>Jefferies added that it believes Atai Beckley's (ATAI) proprietary psychedelics have promise.</li><li>The AdvisorShares Psychedelics ETF (PSIL), which invests in the emerging psychedelic drugs sector, traded 1.3% higher at the time of writing.</li></ul>Jefferies analyst Andrew Tsai now sees positive tailwinds forming for non-recreational psychedelics after President Trump signed an executive order on Thursday directing his administration to reclassify marijuana.The firm now sees non-recreational psychedelics eventually follow suit, as long as sponsors continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health. This, the analyst believes, is arguably a function of time.&nbsp;Jefferies added that it believes pharmaceutical company Atai Beckley's (<a href="https://stocktwits.com/symbol/ATAI">ATAI</a>) proprietary psychedelics have promise. AtaiBeckley’s pipeline includes investigational therapies for treatment-resistant depression and social anxiety disorder.Shares of psychedelics-related stocks rallied on Friday. While ATAI stock traded 0.4% higher at the time of writing, Supernus (<a href="https://stocktwits.com/symbol/SUPN">SUPN</a>) and Cybin (<a href="https://stocktwits.com/symbol/CYBN">CYBN</a>) shares rose about 5%.The AdvisorShares Psychedelics ETF (<a href="https://stocktwits.com/symbol/PSIL">PSIL</a>), which invests in the emerging psychedelic drugs sector, also traded 1.3% higher.<h2 class="st-heading-2">Trump Cannabis Order</h2>President Donald Trump on Thursday <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-stock-rise-as-trump-signs-executive-order-to-lower-marijuana-restrictions/cLegUFuREr0">signed</a> an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.” Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. The Centers for Medicare &amp; Medicaid Services (CMS) is also working on a plan to test making some Medicare patients eligible for therapies derived from cannabinoids or compounds derived from the Cannabis plant.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PSIL fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while sentiment around ATAI also took a dip to ‘extremely bearish’ levels.Sentiment around SUPN stayed ‘neutral,’ while sentiment around CYBN stayed ‘extremely bullish’.A Stocktwits user highlighted a positive study from 2022 on Psilocybin, a naturally occurring psychedelic compound, in treating depression symptoms.<stembedurl>https://www.stocktwits.com/DJS777/message/639663641</stembedurl>As per the study published in the New England Journal of Medicine, participants reported a greater reduction in levels of depression three weeks after taking a 25 mg dose of psilocybin, compared to those who took the lowest 1 mg dose.PSIL has gained 68% this year and by 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-on-track-for-worst-day-in-about-9-months/cLe0RFtREsu">Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.  

AtaiBeckley Inc.

AdvisorShares Psychedelics ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.56	--	--	N/A
Q2 '26	$0.42	$0.53	24.51%	BEAT
Q1 '26	$0.30	$0.60	102.30%	BEAT
Q4 '25	$0.34	$0.85	148.68%	BEAT
Q3 '25	$0.59	$1.01	70.41%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

SUPN Earnings

Upcoming Earnings: Q3 '26

Historical Earnings